3 Biotech Stocks with Massive Upside to Buy before August Starts
Quick Read - REGN sits 15% below its year-start price despite strong earnings, while MRNA has surged 177% into an August 5 FDA flu vaccine ruling. - VKTX carries 175% analyst upside potential but remains pre-revenue, making its dual GLP-1/GIP Phase 3 obesity trials a binary...</p